patients taking isradipine (DynaCirc) have a higher risk of angina
October 1996
The several studies about calcium blockers over the last year have raised huge questions about their safety.
That's why there's so much interest in a brand-new study in JAMA that suggests patients taking isradipine (DynaCirc) have a higher risk of angina...and other adverse events.
These unexpected results come from a study that was designed for a DIFFERENT purpose...to see if either isradipine or HCTZ slows the development of atherosclerosis.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote